Linked Life Data

1441733

Source:http://linkedlifedata.com/resource/pubmed/id/1441733

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1441733rdf:typepubmed:Citationlld:pubmed
pubmed-article:1441733lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C0001060lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C0020964lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:1441733lifeskim:mentionsumls-concept:C0052834lld:lifeskim
pubmed-article:1441733pubmed:issue11lld:pubmed
pubmed-article:1441733pubmed:dateCreated1992-12-1lld:pubmed
pubmed-article:1441733pubmed:abstractTextThe effect of a muramyl dipeptide derivative (B30-MDP) on the augmentation of antitumour immunity against highly metastatic L5178Y-ML25 mouse lymphoma cells was examined in CDF1 (Balb/c x DBA/2) mice. Mice immunized with a mixture of X-irradiated tumour cells (10(3)) and B30-MDP (100 micrograms) on 7 days prior to challenge by viable tumour cells displayed a significant decrease in metastasis towards the target organs, liver and spleen, compared with that of untreated mice. Immunization of mice with the mixture on day 5 or 7 after tumour challenge, when the level of glutamic-pyruvic transaminase (GPT) and glutamic-oxaloacetic transaminase (GOT) in sera of mice inoculated with viable tumour cells was observed to be normal, caused less metastasis than immunization with X-irradiated tumour cells alone. Sensitization with X-irradiated tumour cells admixed with B30-MDP induced almost two times higher cytotoxicity of spleen cells against L5178Y-ML25 lymphoma cells than sensitization with X-irradiated tumour cells without B30-MDP. In contrast, cytotoxic activity of spleen cells against another target, L1210 lymphoma cells derived from BDF1 mice, was not observed by immunization with X-irradiated L5178Y-ML25 cells with or without B30-MDP. Specific lysis by splenic cells of the immunized mice against L5178Y-ML25 cells decreased to the normal level when T cells were deleted from the immunized spleen cells by the treatment of rabbit anti-mouse Thy1.2 antibody and rabbit complement. These results indicate that B30-MDP is able to augment a specific tumour immunity due to the enhancement of cytotoxicity mediated by T lymphocytes, and is useful as an immunopotentiating agent for active immunization of inactivated tumour cells.lld:pubmed
pubmed-article:1441733pubmed:languageenglld:pubmed
pubmed-article:1441733pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1441733pubmed:citationSubsetIMlld:pubmed
pubmed-article:1441733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1441733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1441733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1441733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1441733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1441733pubmed:statusMEDLINElld:pubmed
pubmed-article:1441733pubmed:issn0264-410Xlld:pubmed
pubmed-article:1441733pubmed:authorpubmed-author:SatoKKlld:pubmed
pubmed-article:1441733pubmed:authorpubmed-author:SaikiIIlld:pubmed
pubmed-article:1441733pubmed:authorpubmed-author:AzumaIIlld:pubmed
pubmed-article:1441733pubmed:authorpubmed-author:LULLlld:pubmed
pubmed-article:1441733pubmed:issnTypePrintlld:pubmed
pubmed-article:1441733pubmed:volume10lld:pubmed
pubmed-article:1441733pubmed:ownerNLMlld:pubmed
pubmed-article:1441733pubmed:authorsCompleteYlld:pubmed
pubmed-article:1441733pubmed:pagination792-7lld:pubmed
pubmed-article:1441733pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:meshHeadingpubmed-meshheading:1441733-...lld:pubmed
pubmed-article:1441733pubmed:year1992lld:pubmed
pubmed-article:1441733pubmed:articleTitleB30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.lld:pubmed
pubmed-article:1441733pubmed:affiliationInstitute of Immunological Science, Hokkaido University, Sapporo, Japan.lld:pubmed
pubmed-article:1441733pubmed:publicationTypeJournal Articlelld:pubmed